In this work, a detailed study of Paxlovid and its modifications is done. Paxlovid is an oral drug consisting of two molecules: Nirmatrelvir and Ritonavir . Nirmatrelvir is a small molecule of 35 atoms and satisfies all of the ADME constraints. Ligand GA uses this as the initial population in evolution to find better molecular bindings: better docking fit in the cavity, simpler structurally, better pharmacokinetic activity in the body in particular to the liver enzymes. One of the goals in this work is to produce small molecular modifications to reduce the metabolic rate of the liver eliminating it from the body; this in conjunction with significantly increasing the interaction with the Mpro site. Together this could eliminate the need for the added drug Ritonavir which has consequences of severely limiting Paxlovid's general use.